|
|
|
|
|
|||||||
|
Session 16
Oral Abstract Session
Active and Passive Immunization Studies Tuesday, 10 am - 12:30 pm 6E |
| Moderators | Barney Graham, NIAID Vaccine Res. Ctr., NIH, Bethesda, MD and Judith Wasserheit, Fred Hutchinson Cancer Res. Ctr., Seattle, WA | ||
| 10:00 71. | Both Innate and Adaptive Immune Responses Confer Protection in SHIV89.6 Infected Rhesus Macaques Challenged with Pathogenic SIVmac239 K. Abel*1,2 , L. Compton1, T. Rourke2, D. Lu1,2, L. Fritts2, C. J. Miller1,2, and 1Ctr. for Comparative Med., Davis, CA; 2California Regional Primate Res. Ctr., Davis; and 3Sch. of Veterinary Med., Univ. of California, Davis
| ||
| 10:15 72. | Immunogenicity and Protective Efficacy of ISS ODN Adjuvanted Inactivated SIV Containing Functional Envelope Glycoprotein against IV SIVmac239 Challenge L. O. Arthur1, J. L. Rossio1, M. Piatak Jr.1, B. M. Flynn2, R. C. Desrosiers3, J. Hoxie4, E. Raz5, D. D. Richman5, G. VanNest6, L. Henderson1, and J. D. Lifson*1 1SAIC, Frederick, MD; NCI, Frederick, MD; 2NCI, NIH, Bethesda, MD; 3New England Regional Primate Res. Ctr., Harvard Med. Sch., Southborough, MA; 4Univ. of Pennsylvania, Philadelphia; 5Univ. of California, San Diego; and 6Dynavax Technologies, Emeryville, CA
| ||
| 10:30 73. | Vaccination with Autologous Dendritic Cells Pulsed with AT-2-Inactivated Whole Virus Provides Partial Protection from Pathogenic SIV Challenge Y.-D. Zhu*1, K. Koo1, 2, W. Sutton1, L. Kuller3, S.-L. Hu2, 3, R. Benveniste4, E. Thomas5, J. D. Lifson6, and N. Haigwood1 1Seattle BioMed. Res. Inst., WA; 2Univ. of Washington, Seattle; 3Regional Primate Res. Ctr., Seattle, WA; 4NCI, NIH, Bethesda, MD; 5Immunex Corp., Seattle, WA; and 6SAIC, Frederick, MD
| ||
| 10:45 74. | Viremia Containment Following Mucosal Challenge with SIVmac251 Correlates with SIV-Specific CTL and Lymphoproliferative Responses Induced by a DNA-SIV and NYVAC-SIV Prime/Boost Regimen Z. Hel*1, J. Nacsa1 , E. Tryniszewska1, 2 , W-P. Tsai1 , D. Montefiori3 , B. K. Felber4 , G. N. Pavlakis4 , J. Tartaglia5, and G. Franchini1 1NCI, NIH, Bethesda, MD; 2Med. Academy of Bialystok, Poland; 3Duke Univ. Med. Ctr., Durham, NC; 4NCI, NIH, Frederick, MD; and 5Aventis-Pasteur, Toronto, ON, Canada
| ||
| 11:00 75. | Enhanced Protective Efficacy of Vaccinia Virus/Protein Vaccine Regimen Containing Polyvalent Envelope Against a Pathogenic SHIV in Rhesus Macaques Y. B. Kim1, D. P. Han1, R. Willey1, R. Plishka1, A. Buckler-White1, R. Byrum2, M. A. Martin1, and M. W. Cho*1 1NIH, Bethesda, MD; and 2Bioqual, Rockville, MD
| ||
| 11:15 76. | Passive Neutralizing IgG Treatment During the Acute Phase Improves Host Immunity and Disease Outcome in SIV-Infected Macaques N. Haigwood*1, 2, P. Choi2, J. Fischer1, W. Sutton1, K. Yaraei1, B. Richardson2, 3, L. Kuller3, D. Anderson3, S.-L. Hu2, 3, and V. Hirsch4 1Seattle BioMed. Res. Inst., WA; 2Univ. of Washington, Seattle; 3Regional Primate Res. Ctr, Seattle, WA; and 4NIAID, NIH, Rockville, MD
| ||
| 11:30 77. | Neutralizing Antibodies Applied to the Mucosal Surface, or Preincubated with Challenge Virus ex Vivo, Fail to Protect Macaques Against SHIV-Challenge M. G. Lewis*1, J. Greenhouse1, J. Yalley-Ogunro1, N. Shaw1, P. Silvera1, T. C. VanCott2, G. Stiegler3, H. Katinger3, and J. R. Mascola4 1Southern Res. Inst. Frederick, MD; 2Henry M. Jackson Fndn., Rockville, MD; 3Inst. Applied Microbiology, Univ. Agriculture, Vienna, Austria; and 4NIAID Vaccine Res. Ctr., NIH, Bestheda, MD
| ||
| 11:45 78. | Novel Broadly Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibody Selected for Binding to gp120-CD4-CCR5 Complexes M. Moulard1, S. Phogat*2, Y. Shu2, X. Xiao2, P. W. H. I. Parren1, J. M. Binley1, M. Zhang2, J. Robinson3, D. R. Burton1, and D. S. Dimitrov2 1Scripps Res. Inst., La Jolla, CA; 2 NCI, NIH, Frederick, MD; and 3Tulane Univ. Med. Ctr., New Orleans, LA
| ||
| 12:00 79. | Construction and Characterization of HIV-1 Subtype-C-Based, Dual-Promoter DNA Vaccines Y. Huang*, Z. Chen, W. Zhang, Y. Song, D. Gurner, and D. Ho Aaron Diamond AIDS Res. Ctr., Rockefeller Univ., New York, NY
| ||
| 12:15 80. | Improved Candidate DNA Vaccines against HIV-1 M. Rosati*1, P. Eyler1, A. Valentin1, H. Trivedi1, A. Biragyn1, L. W. Kwak1, P. Markham2, R. Woodward2, A. von Gegerfelt1, N. Miller3, B. K. Felber1, and G. N. Pavlakis1 1NCI, NIH, Frederick, MD; 2Advanced BioSci. Labs., Inc., Kensington, MD; and 3NIAID, NIH, Bethesda, MD
|
